Evidence map›Paper›PMID 39464730›Full record

ArticleVirusdisease2024

Genome sequencing of SARS-Co-V-2 reveals mutations including F559I and V781D in S protein and LI123-124L in the nsp6 in 21K and 21L clades.

Mohamed G Seadawy, Mohamed I Marei, Marwa Mohanad, Ahmed A Hmed, Ahmed R Sofy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virusdisease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed G SeadawyBiodefense Center for Infectious and Emerging Diseases, Ministry of Defense, Cairo, Egypt.ORCID 0000-0001-6102-723X
Mohamed I MareiBiodefense Center for Infectious and Emerging Diseases, Ministry of Defense, Cairo, Egypt.
Marwa MohanadBiochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, Egypt.
Ahmed A HmedBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, 11884 Egypt.
Ahmed R SofyBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, 11884 Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contagious and virulent virus variants like B.1.1.529 have complicated the 2019 global COVID-19 pandemic from Wuhan, China. Omicron, with extensive mutations and high transmissibility, is replacing Delta in some regions. Remarkably, Omicron exhibits reduced disease severity and resistance to certain vaccines and treatments. Our research sought to identify Egypt-specific variants of concern (VOCs) and their mutation patterns, aiming to provide critical insights for tailored public health strategies. We also looked at vaccine compatibility with these VOCs, as well as the efficacy of current treatments against new SARS-CoV-2 variants

Indexed as

F559IMitigation strategiesNext-generation sequencingSARS-CoV-2V781D

Identifiers

PMID39464730
PMCPMC11502607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.